Study wrapper · #110
Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.
Editor's note
A 30-week prospective, non-interventional cohort of 217 adults with type 2 diabetes in Pakistan, examining a locally produced biosynthetic semaglutide in routine care. The reported results are substantial and directionally consistent with the registration trials: mean HbA1c fell from 9.27% to 7.41% (a 1.86-point drop), mean weight fell 7.84 kg, and roughly three-quarters achieved at least 5% weight loss. Adverse events were mostly non-serious and gastrointestinal, with no severe hypoglycemia reported. The value here is real-world, cost-constrained context, a population and setting under-represented in the SUSTAIN program. But the design limits interpretation: single-arm and non-interventional means no comparator, so regression to the mean, concurrent care changes, and the high baseline HbA1c (leaving more room to fall) all inflate apparent effect. It is also observational, not randomized. This is supportive real-world evidence that a biosynthetic preparation behaved consistently with established semaglutide over 30 weeks, not proof of equivalence.
Plain-language abstract
This study followed 217 adults with type 2 diabetes in Pakistan for about 30 weeks as they started a locally made version of semaglutide during ordinary clinic care. There was no comparison group, everyone received the drug, and researchers simply measured changes over time. The main outcome was long-term blood sugar, measured as HbA1c. On average it dropped from 9.27% to 7.41%, an improvement of 1.86 points, and about 77% of patients reached an HbA1c under 8%. Average body weight fell by 7.84 kg, and roughly three-quarters of patients lost at least 5% of their weight. Waist size and BMI also went down, and patients reported greater treatment satisfaction and better physical quality of life. Side effects were mostly minor and involved the stomach and gut (such as nausea), and no severe low-blood-sugar episodes were reported. The authors say these results match what is known about standard semaglutide. Because there was no comparison group, the study cannot prove the medication alone caused all the improvement.